Unknown

Dataset Information

0

Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment.


ABSTRACT: Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant (n = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of Akkermansia muciniphila, a species of mucin-degrading bacteria (P = 0.006, corrected for multiple comparisons). Two therapies that induce neutropenia, irradiation and melphalan, similarly expanded A. muciniphila and additionally thinned the colonic mucus layer in mice. Caloric restriction of unirradiated mice also expanded A. muciniphila and thinned the colonic mucus layer. Antibiotic treatment to eradicate A. muciniphila before caloric restriction preserved colonic mucus, whereas A. muciniphila reintroduction restored mucus thinning. Caloric restriction of unirradiated mice raised colonic luminal pH and reduced acetate, propionate, and butyrate. Culturing A. muciniphila in vitro with propionate reduced utilization of mucin as well as of fucose. Treating irradiated mice with an antibiotic targeting A. muciniphila or propionate preserved the mucus layer, suppressed translocation of flagellin, reduced inflammatory cytokines in the colon, and improved thermoregulation. These results suggest that diet, metabolites, and colonic mucus link the microbiome to neutropenic fever and may guide future microbiome-based preventive strategies.

SUBMITTER: Schwabkey ZI 

PROVIDER: S-EPMC10028729 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment.

Schwabkey Zaker I ZI   Wiesnoski Diana H DH   Chang Chia-Chi CC   Tsai Wen-Bin WB   Pham Dung D   Ahmed Saira S SS   Hayase Tomo T   Ortega Turrubiates Miriam R MR   El-Himri Rawan K RK   Sanchez Christopher A CA   Hayase Eiko E   Frenk Oquendo Annette C AC   Miyama Takahiko T   Halsey Taylor M TM   Heckel Brooke E BE   Brown Alexandria N AN   Jin Yimei Y   Raybaud Mathilde M   Prasad Rishika R   Flores Ivonne I   McDaniel Lauren L   Chapa Valerie V   Lorenzi Philip L PL   Warmoes Marc O MO   Tan Lin L   Swennes Alton G AG   Fowler Stephanie S   Conner Margaret M   McHugh Kevin K   Graf Tyler T   Jensen Vanessa B VB   Peterson Christine B CB   Do Kim-Anh KA   Zhang Liangliang L   Shi Yushu Y   Wang Yinghong Y   Galloway-Pena Jessica R JR   Okhuysen Pablo C PC   Daniel-MacDougall Carrie R CR   Shono Yusuke Y   Burgos da Silva Marina M   Peled Jonathan U JU   van den Brink Marcel R M MRM   Ajami Nadim N   Wargo Jennifer A JA   Reddy Pavan P   Valdivia Raphael H RH   Davey Lauren L   Rondon Gabriela G   Srour Samer A SA   Mehta Rohtesh S RS   Alousi Amin M AM   Shpall Elizabeth J EJ   Champlin Richard E RE   Shelburne Samuel A SA   Molldrem Jeffrey J JJ   Jamal Mohamed A MA   Karmouch Jennifer L JL   Jenq Robert R RR  

Science translational medicine 20221116 671


Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant (<i>n</i> = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of <i>Akkermansia muciniphila</i>, a species of mucin-degrading bacteria (<i>P</i> = 0.006, correc  ...[more]

Similar Datasets

| S-EPMC9456539 | biostudies-literature
| S-EPMC5880543 | biostudies-literature
| S-EPMC10413624 | biostudies-literature
| S-EPMC8698669 | biostudies-literature
| S-EPMC9782760 | biostudies-literature
| S-EPMC10360209 | biostudies-literature
| S-EPMC8293987 | biostudies-literature
| S-EPMC10337958 | biostudies-literature
| PRJEB46578 | ENA
| S-SCDT-10_15252-EMMM_202217241 | biostudies-other